MedTrace Logo

To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy

NCT01302899 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2013-01-30

Study results available
· View outcomes & findings →

Summary

The study is designed to primarily assess the effect of aliskiren on albuminuria in patients with non-diabetic nephropathy when treated with ramipril and volume intervention.

Conditions

  • Non-diabetic Nephropathy

Interventions

DRUG

Aliskiren

Aliskiren 150 mg (Tablet)

DRUG

Placebo to Aliskiren

Aliskiren 150 mg Matching Placebo (Tablet)

DRUG

Hydrochlorothiazide (HCTZ)

HCTZ 25mg (Capsule)

DRUG

Placebo to Hydrochlorothiazide (HCTZ)

HCTZ 25mg (Capsule) Matching Placebo

DRUG

Ramipril

Ramipril 10mg (Tablet)

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01302899 on ClinicalTrials.gov